EFFICACY AND SAFETY OF PYRONARIDINE TETRAPHOSPHATEARTESUNATE FOR TREATMENT OF UNCOMPLICATED Plasmodium falciparum MALARIA IN BINH PHUOC, GIA LAI AND PHU YEN PROVINCES, VIET NAM, IN 2021

Tóm tắt

From March to December 2021, this prospective, open-label, single-arm
observational clinical trial, conducted in Binh Phuoc, Gia Lai and Phu Yen provinces,
evaluated the safety and efficacy of oral Pyronaridine tetraphosphate-Artesunate oncedaily for three consecutive days in adults and children with microscopically confirmed
P. falciparum malaria. Patients were treated as in-patients for Days 0–3, with followup visits on Days 7, 14, 21, 28, 35 and 42. The primary outcome was PCR-adjusted
adequate clinical and parasitological response (ACPR) at Day 42. The results from 54
P. falciparum patients has shown that: The efficacy of Pyronaridine tetraphosphate -
Artesunate to P. falciparum has still high, with the rate of ACPR is 100%, the rate of
positive parasitemia at day 3 is 50%, 54.5% and 54.8% in Binh Phuoc, Phu Yen and
Gia Lai, respectively. Pyronaridine-Artesunate is safety for the patients. None serious
adverd event are recorded.